News | April 06, 2012

St. Jude Medical Announces Third-Party Validation, Analysis of Leads Registry Data

April 6, 2012 — St. Jude Medical Inc. announced it has appointed Population Health Research Institute (PHRI), an academic health science research institute, to analyze data from three combined registries on the Riata ST Optim and Durata implantable cardioverter defibrillator (ICD) leads. The analysis will be entirely under the control of PHRI, who will complete a review of the performance of the leads.

Under the agreement, PHRI will receive the raw data and independently design and perform analyses from three ongoing prospective, actively monitored registries monitoring the performance of the Riata ST Optim and Durata leads: the OPTIMUM, SCORE and DF4 Post-Approval studies, all sponsored by St. Jude Medical. The combined data from these studies currently represents over 10,000 leads implanted at 292 sites, with more than 24,000 patient-years of data collected over the more than five years that the leads have been on the market.

“We take our responsibilities as a leading manufacturer of cardiac rhythm management devices very seriously and recognize our primary responsibility as a global medical device manufacturer is to ensure that our devices are of the highest quality and that they function safely and properly,” said Mark Carlson, chief medical officer and senior vice president of research and clinical affairs for the St. Jude Medical cardiac rhythm management division. “We are pleased to enlist PHRI to perform an independent analysis and validation of the Optim insulated defibrillation lead data from these three very large, long-term registries.”

PHRI will convene a committee of independent physicians chaired by Dr. John Cairns, an internationally recognized expert in cardiology clinical trials, professor of medicine and former dean of medicine at the University of British Columbia, who has no affiliations with the cardiac rhythm management industry. Additional committee members include Stuart Connolly, M.D., professor and director of the division of cardiology at McMaster University; Jeff Healey, M.D., associate professor of cardiology at McMaster University; Andrew Epstein, M.D., professor of medicine at the University of Pennsylvania and chief of cardiology at the Philadelphia Veterans Administration Medical Center; and Christopher Buller, M.D., professor of medicine at the University of Toronto and director of cardiac catheterization and intervention at St. Michael’s Hospital.

The committee will function independently of the company, meeting with the company to initiate the project but conducting work in private. The committee will meet on an ongoing basis for at least two years to review data as it is collected. Data analysis would be performed on an ongoing basis with accumulating data and the results would be published in St. Jude Medical biannual product performance reports and made available on the St. Jude Medical website. The committee may also independently publish its findings.

For more information: www.sjm.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init